RxDoctor Payments Data

Idayli Perez Rodriguez

General Practice · Homestead, FLNPI 1174040497

Payments from drug & device makers

$569in general payments, 2019–2025

Across 36 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$244
  • AstraZeneca$130
  • Boehringer Ingelheim$74
  • Amgen$53
  • Bayer$39
  • Pfizer$15
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$569100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC17$244
AstraZeneca8$130
Boehringer Ingelheim4$74
Amgen3$53
Bayer2$39
Pfizer1$15
GSK1$13

How this compares

$569 in reported general payments places this provider in the 65th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$3,341
Medicare patients
13
Services billed
51

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin164$122,040
EliquisApixaban120$84,790
OzempicSemaglutide60$57,754
FarxigaDapagliflozin Propanediol44$26,881
XareltoRivaroxaban41$25,370
TrulicityDulaglutide22$24,168
JanuviaSitagliptin Phosphate38$21,802
TradjentaLinagliptin27$21,375
MounjaroTirzepatide13$15,595
Soliqua 100-33Insulin Glargine/Lixisenatide18$13,334
SynjardyEmpagliflozin/Metformin Hcl12$10,621
SymbicortBudesonide/Formoterol Fumarate34$8,968
Combivent RespimatIpratropium/Albuterol Sulfate15$7,246
InvokametCanagliflozin/Metformin Hcl11$6,192
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$5,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Combivent Respimat$74$161,282218 claims
PfizerEliquis$15$84,790120 claims
Lilly USA, LLCTrulicity, Mounjaro$244$39,76335 claims
AstraZenecaFarxiga, Symbicort$130$35,85078 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,901 general practice providers in Florida.

Other general practice in Homestead

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →